This is now a contrarian view to think these molecular diagnostic can sustain top line growth after covid testing volume drops over time. Gss was growing well before covid and covid will only have accelerated its growth. I think this contrarian view will be profitable in the near future. Back the management who has been executing well time after time.
- Forums
- ASX - By Stock
- GSS
- Global expansion post Covid 19
GSS
genetic signatures limited
Add to My Watchlist
1.45%
!
34.0¢

Global expansion post Covid 19, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $77.22M |
Open | High | Low | Value | Volume |
35.0¢ | 35.0¢ | 33.0¢ | $19.92K | 58.59K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2689 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.5¢ | 14354 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2689 | 0.330 |
1 | 10000 | 0.320 |
2 | 30000 | 0.315 |
1 | 50000 | 0.310 |
2 | 51374 | 0.300 |
Price($) | Vol. | No. |
---|---|---|
0.365 | 14354 | 1 |
0.380 | 103638 | 3 |
0.395 | 2534 | 1 |
0.400 | 8000 | 1 |
0.415 | 2412 | 1 |
Last trade - 15.37pm 28/07/2025 (20 minute delay) ? |
Featured News
GSS (ASX) Chart |